Alkermes (ALKS)
(Delayed Data from NSDQ)
$24.54 USD
-0.34 (-1.37%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $24.54 0.00 (0.00%) 4:44 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Brokerage Reports
Alkermes plc [ALKS]
Reports for Purchase
Showing records 1 - 20 ( 282 total )
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Solid 4Q, Upbeat Outlook For the ''New'' Alkermes; PT up to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for ALKS 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
3Q Shows Some Softness, Though "New" Alkermes Comes Into Focus; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Company: Alkermes plc
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department